{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:38:41Z","timestamp":1765827521821},"reference-count":37,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.3892\/mmr.2016.5779","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T09:44:41Z","timestamp":1474883081000},"page":"4180-4186","source":"Crossref","is-referenced-by-count":10,"title":["Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM-1 human myelodysplastic syndrome cell line"],"prefix":"10.3892","volume":"14","author":[{"given":"Hai-Ying","family":"Hua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Ning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Nong","family":"Cen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"key20180108025854_b1-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: High number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"key":"key20180108025854_b2-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2796.2008.02052.x","article-title":"Myelodysplastic syndromes: Biology and treatment","volume":"265","author":"J\u00e4dersten","year":"2009","journal-title":"J Intern Med"},{"key":"key20180108025854_b3-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180108025854_b4-mmr-14-05-4180","first-page":"S2","article-title":"Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes","volume":"16","author":"Gore","year":"2009","journal-title":"Cancer Control"},{"key":"key20180108025854_b5-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2007-02-076307","article-title":"Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"key20180108025854_b6-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2008.10.012","article-title":"Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: Importance of pretransplant disease burden","volume":"15","author":"Warlick","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20180108025854_b7-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20180108025854_b8-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","article-title":"A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial","volume":"98","author":"Gore","year":"2013","journal-title":"Haematologica"},{"key":"key20180108025854_b9-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"key20180108025854_b10-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/sj.leu.2403934","article-title":"Low-dose cytosine arabinoside (LD-AraC) vs. LD-AraC plus granulocyte\/macrophage colony stimulating factor vs. LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group","volume":"19","author":"Zwierzina","year":"2005","journal-title":"Leukemia"},{"key":"key20180108025854_b11-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","article-title":"High-dose chemotherapy in high-risk myelodysplastic syndrome: Covariate-adjusted comparison of five regimens","volume":"92","author":"Beran","year":"2001","journal-title":"Cancer"},{"key":"key20180108025854_b12-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180108025854_b13-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMe1202819","article-title":"Lenalidomide in myeloma-a high-maintenance friend","volume":"366","author":"Badros","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180108025854_b14-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.molmed.2011.10.001","article-title":"Curing APL through PML\/RARA degradation by As2O3","volume":"18","author":"Lallemand-Breitenbach","year":"2012","journal-title":"Trends Mol Med"},{"key":"key20180108025854_b15-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen","year":"1997","journal-title":"Blood"},{"key":"key20180108025854_b16-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2005.03.7903","article-title":"Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes","volume":"24","author":"Schiller","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108025854_b17-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2005.03.9503","article-title":"Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study","volume":"24","author":"Vey","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108025854_b18-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/1871520611009060504","article-title":"Combination therapy with arsenic trioxide for hematological malignancies","volume":"10","author":"Takahashi","year":"2010","journal-title":"Anticancer Agents Med Chem"},{"key":"key20180108025854_b19-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.3390\/ijms13089627","article-title":"Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer","volume":"13","author":"Xia","year":"2012","journal-title":"Int J Mol Sci"},{"key":"key20180108025854_b20-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"817","DOI":"10.5604\/17322693.1061640","article-title":"Arsenic trioxide: Impact on the growth and differentiation of cancer cells and possible use in cancer therapy","volume":"67","author":"Hoffman","year":"2013","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"key20180108025854_b21-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s11033-009-9765-2","article-title":"Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis","volume":"37","author":"Zhao","year":"2010","journal-title":"Mol Biol Rep"},{"key":"key20180108025854_b22-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.toxlet.2013.03.024","article-title":"Arsenic trioxide induces cardiac fibroblast apoptosis in vitro and in vivo by up-regulating TGF-\u03b21 expression","volume":"219","author":"Li","year":"2013","journal-title":"Toxicol Lett"},{"key":"key20180108025854_b23-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1756-8722-3-28","article-title":"Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells","volume":"3","author":"Yedjou","year":"2010","journal-title":"J Hematol Oncol"},{"key":"key20180108025854_b24-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2125.2012.04221.x","article-title":"Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases","volume":"74","author":"Han","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"key20180108025854_b25-mmr-14-05-4180","first-page":"434","article-title":"Study of triptolide-induced apoptosis in MUTZ-1 cells and its allied mechanism","volume":"13","author":"Deng","year":"2005","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20180108025854_b26-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2010.04.046","article-title":"Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways","volume":"139","author":"Mujumdar","year":"2010","journal-title":"Gastroenterology"},{"key":"key20180108025854_b27-mmr-14-05-4180","first-page":"551","article-title":"Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway","volume":"25","author":"Wu","year":"2011","journal-title":"Oncol Rep"},{"key":"key20180108025854_b28-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/aps.2010.237","article-title":"Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-\u03baB activity and miR-16-1*","volume":"32","author":"Meng","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"key20180108025854_b29-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/cncr.25686","article-title":"A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"key":"key20180108025854_b30-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20180108025854_b31-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzym Regul"},{"key":"key20180108025854_b32-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1532\/IJH97.06076","article-title":"Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication","volume":"84","author":"Takahashi","year":"2006","journal-title":"Int J Hematol"},{"key":"key20180108025854_b33-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.fsi.2011.01.018","article-title":"Molecular cloning and characterization of caspase-3 in large yellow croaker (Pseudosciaena crocea)","volume":"30","author":"Li","year":"2011","journal-title":"Fish Shellfish Immunol"},{"key":"key20180108025854_b34-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jss.2010.03.067","article-title":"Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma","volume":"163","author":"Clawson","year":"2010","journal-title":"J Surg Res"},{"key":"key20180108025854_b35-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3892\/ijo.2011.1273","article-title":"Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression","volume":"40","author":"Spampanato","year":"2012","journal-title":"International J Onco"},{"key":"key20180108025854_b36-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.7314\/APJCP.2015.16.16.7103","article-title":"Induction of P3NS1 myeloma cell death and cell cycle arrest by simvastatin and\/or \u03b3-radiation","volume":"16","author":"Abdelrahman","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20180108025854_b37-mmr-14-05-4180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1535-7163.MCT-06-0349","article-title":"Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells","volume":"6","author":"Park","year":"2007","journal-title":"Mol Cancer Ther"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2016.5779\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T07:42:42Z","timestamp":1601106162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2016.5779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,9,26]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.3892\/mmr.2016.5779"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2016.5779","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]}}}